Several key pivotal trials have demonstrated its relative treatment efficacy versus standard chemotherapy alone, in improving the disease-free and overall survival of HER2-positive early-stage breast cancer (EBC) patients [9–16]. The gene discussed is ERBB2; the disease is breast cancer.